Mediwhale
June 18, 2025
Company Presentation
Cardiovascular
153C
We empower individuals to assess their health through retinal imaging. Our product, Dr. Noon, is an AI-based tool that identifies risks for cardiovascular, kidney, and eye diseases. It’s fully commercialized and currently in use across Korea, Europe, the Middle East, and Southeast Asia.
Our technology is backed by robust clinical evidence, with key studies published in leading journals such as The Lancet Digital Health and European Heart Journal Digital Health, and others.
Company HQ City:
Gangnam-gu
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2016
Lead Product in Development:
Medical A.I.
Software as a Medical Device
CEO
Kevin Choi, BS
Tyler Rim, MD PHD MBA
Development Phase of Lead Product
Other/Not Applicable
What is your next catalyst (value inflection) update?
Our solution "Dr. Noon"is regulatory approved in 8 territories, it has successfully commercialized and secured reimbursement AI code as the first case for outpatient use in South Korea.
Expecting FDA approval in first half of 2026.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}